Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review Article

Free Access

Early Discriminatory Diagnosis of Dementia with Lewy Bodies

The Emerging Role of CSF and Imaging Biomarkers
Aarsland D.a, c · Kurz M.a · Beyer M.b · Bronnick K.a · Piepenstock Nore S.d · Ballard C.e

Author affiliations

aNorwegian Centre for Movement Disorders and bDepartment of Radiology, Stavanger University Hospital, Stavanger, and cInstitute of Clinical Medicine, University of Bergen, and dGeriatric section, Haraldsplass Deaconess University Hospital, Bergen, Norway; eWolfson Centre for Age-Related Diseases, King’s College London, London, UK

Corresponding Author

Dag Aarsland

Stavanger University Hospital

Arm Hansen v 20

NO–4005 Stavanger (Norway)

Tel. +47 5151 5062, Fax +47 5151 5195, E-Mail daarsland@gmail.com

Related Articles for ""

Dement Geriatr Cogn Disord 2008;25:195–205

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: The clinical diagnostic criteria for dementia with Lewy bodies (DLB) have a low sensitivity, and there are no generally accepted biomarkers to distinguish DLB from other dementias. Our aim was to identify biomarkers that may differentiate DLB from Alzheimer’s disease (AD). Method: We performed a systematic literature search for studies of EEG, imaging techniques and genetic and CSF markers that provide sensitivity and specificity in the identification of DLB. Results: The best evidence was for scintigraphy of the striatal dopamine transporter system using FP-CIT SPECT. Several small scintigraphy studies of cardiovascular autonomic function using metaiodobenzylguanidine SPECT have reported promising results. Studies exploring innovative techniques based on CSF have reported interesting findings for the combination of amyloid β (aβ) isoforms as well as α-synuclein, and there are interesting results emerging from preliminary studies applying proteomic techniques. Data from studies using structural MRI, perfusion SPECT, genetics and EEG studies show differences between DLB and AD but only at a group level. Conclusion: Several potential biomarkers for the differential diagnosis of probable DLB and AD have shown good diagnostic accuracy in the research setting. Data from large multicentre studies and from studies with autopsy confirmation exist for scintigraphy of the dopamine transporter system. Future studies should explore its value in possible DLB and for clinical management and health economics.

© 2008 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review Article

Accepted: October 21, 2007
Published online: January 17, 2008
Issue release date: March 2008

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 1

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.